Document:

exv10w1

 

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 on the Securities Exchange Act of 1934, as amended.

Exhibit 10.1

July 26, 2005

Dr. Kurt Konopitzky

Head Division Biopharmaceutical Operations

Boehringer Ingelheim Austria GmbH

Dr. Boehringer-Gasse 5 — 11

A-1121 Vienna, Austria

			
	Re:	 	Amendment No. 3 to the Data Transfer, Clinical Trial and Market Supply Agreement, dated as of
January 27, 2000

Dear Mr. Kanzler;

          As you know, InterMune, Inc. (“InterMune”) and Boehringer Ingelheim Austria GmbH (“BI
Austria”) are parties to that certain Data Transfer, Clinical Trial and Market Supply Agreement
effective January 27, 2000, as amended effective June 19, 2002 and as further amended effective
September 18, 2003 (the “Agreement”). This letter (this “Amendment”) will confirm our agreement to
amend and supplement the Agreement as follows, effective as of the date first set forth above:

	 	1.	 	The parties hereby agree that InterMune’s obligation to purchase [ * ] of [ *
] vials of the PRODUCT for [ * ] pursuant to Section 3.2.1 of the Agreement is
hereby waived without further payment or any liability or penalty to InterMune with
regard to the aforementioned waiver.
	 
	 	2.	 	The parties hereby agree that InterMune’s obligation to purchase [ * ] of [ *
] vials of the PRODUCT for [ * ] pursuant to Section 3.2.1 of the Agreement shall be
[ * ] vials for such [ * ] without liability or penalty to InterMune with regard to
the aforementioned [ * ] . The parties further hereby agree that with respect to such
[ * ] vials that InterMune is required [ * ] to purchase in [ * ] pursuant to
Section 3.2.1 of the Agreement after giving effect to the modification thereto as set
forth in this Section 3 of this Amendment, such vials will be produced by BI Austria in
the [ * ] for delivery to InterMune in the [ * ] and such vials will have [ * ] of
in the second calendar quarter of [ * ] .
	 
	 	3.	 	The Agreement is hereby amended to delete the second (2nd) paragraph
of Section 3.2.1 and replace such paragraph with the following:

	 	 	“Following BI Austria’s and BI Pharma KG’s FDA approval to manufacture

 

 

	 	 	PRODUCT for market supply, InterMune shall order the requested amounts of
PRODUCT. In any case, the [ * ] of PRODUCT ordered by InterMune shall be as
follows: [ * ] per year for delivery in each calendar year through calendar year [
* ] ; (ii) [ * ] vials of PRODUCT per year for delivery in [ * ] ; provided,
however, that for [ * ] , the [ * ] of PRODUCT ordered by InterMune shall be [ * ]
vials of Product and provided, further, that for [ * ] , instead of InterMune having
any [ * ] , InterMune, for the remainder of the term of the Agreement, shall [ * ]
annual purchases of PRODUCT [ * ] equal to [ * ] such that if at the end of a
given year InterMune purchases less than [ * ] in PRODUCT, InterMune shall pay to
BI Austria the difference between [ * ] and that amount in PRODUCT actually
purchased by InterMune during such year.”

	 	4.	 	The first sentence of Section 3.2.6 of the Agreement shall be deleted and
replaced with the following sentence:

	 	 	     “If InterMune determines that [ * ] vials of PRODUCT, or the [ * ] as
applicable, per year exceeds InterMune’s annual requirements for PRODUCT [ * ]
then InterMune may so notify BI Austria, stating the number of vials of PRODUCT
or the [ * ] , as applicable, that InterMune predicts will actually require
going forward from the date of InterMune’s notice (the “Revised Level”).”

	 	5.	 	The Agreement is hereby amended to add the following language at the end of
Section 3.3.4:

	 	 	“With respect to PRODUCTS ordered by InterMune for [ * ] requirements, the
number of vials supplied by BI Austria shall not exceed the number of vials
subject to the applicable purchase order submitted by InterMune; provided,
however, that if the number of vials BI Austria is able to supply [ * ] the
number of vials ordered by InterMune in such purchase order and [ * ] is [ * ]
the number ordered by InterMune, BI Austria shall notify InterMune in writing
and inquire as to whether [ * ] is acceptable and if not, whether BI
Austria should [ * ] . If InterMune notifies BI Austria that such [ * ] is
acceptable to InterMune, then the applicable purchase order shall be deemed to
be amended to provide for [ * ] and BI Austria shall be deemed to have accepted
such purchase order in accordance with Section 3.3. On the other hand, if
InterMune notifies BI Austria that BI Austria should [ * ] , then BI Austria
shall be obligated to produce [ * ] InterMune shall be obligated to purchase
[ * ] vials of PRODUCT produced by BI Austria from [ * ] and the purchase
order submitted to BI Austria by InterMune shall be deemed amended to account [
* ] resulting from the [ * ] and such purchase order shall be deemed accepted
by BI Austria in accordance with Section 3.3.”

[ * ] = certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the securities and exchange
commission pursuant to rule 24b-2 on the securities exchange act
of 1934, as amended.

 

 

	 	6.	The Agreement is hereby amended to add a new Section 3.7.3 after Section 3.7.2
hereof as follows:
	 
	 	 	“3.7.3 	    In addition, the parties, through the STEERING COMMITTEE shall work together in
good faith to develop a risk mitigation plan to minimize any risk of interruption
in the supply of PRODUCT for use in clinical trials and market supply, which plan
may include, among other things, [ * ] and/or [ * ] .”

	 	7.	 	The Agreement is hereby amended by adding at the end of Section 4.1 the
following paragraph:
	 
	 	 	 	     “Payments by InterMune to BI Austria hereunder shall be in Euros; provided,
however, that on each invoice, the applicable exchange rate to convert Euros to US
Dollars as of the invoice date shall be noted. For purposes of InterMune’s payments to
BI Austria hereunder, the foreign currency exchange rate will be [ * ] such that any
gain or loss resulting from exchange rate fluctuation outside [ * ] of the [ * ] will
be shared [ * ] between BI Austria and InterMune and payments owed by InterMune to BI
Austria will be adjusted to reflect such sharing of foreign exchange risks.”

	 	8.	 	The Agreement is hereby amended by deleting Section 13.1 in its entirety and
replacing it with the following:

	 	 	 	“13.1 Duration

	 	 	 	The Agreement shall be effective as of the Effective Date and shall continue
in force until December 31, 2012. This Agreement shall automatically renew
for successive four (4) year periods, provided, however, that either Party
may elect not to renew this Agreement by providing the other Party written
notice of such election at least thirty-six (36) months prior to the date of
expiration of the then-current term. In addition, in the event that results
from InterMune’s Phase III clinical trial for idiopathic pulmonary fibrosis
(GIPF 007) (“Inspire Trial”) and/or InterMune’s Phase III clinical trial for
ovarian cancer (GIOV-001) (“Graces Trial”) are positive so as to cause
InterMune to decide to proceed with filing a BLA, InterMune shall have the
option exercisable with prior written notice to BI Austria to extend the
initial term of the Agreement from December 31, 2012 to a period of time up
to December 31, 2021.”

	 	9.	 	The Agreement is hereby amended to delete in its entirety Section 14.4 and
replace it with the following:

	 	 	 	“14.4 Notices

[ * ] = certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the securities and exchange
commission pursuant to rule 24b-2 on the securities exchange act
of 1934, as amended.

 

 

	 	 	 	Any notice required or permitted to be given hereunder by either Party shall
be in writing and shall be (i) delivered personally, (ii) sent by registered
mail, return receipt requested, postage prepaid or (iii) delivered by
facsimile and confirmed by certified or registered mail to the addresses or
facsimile numbers set forth below:

	 	 	 	 	 
	 

	 	If to InterMune:
	 	InterMune, Inc.
	 

	 	 	 	3280 Bayshore Boulevard
	 

	 	 	 	Brisbane, CA 94005 USA
	 

	 	 	 	Facsimile: +1 — 415 — 466 — 2300
	 

	 	 	 	Attention: Russell Kawahata
	 
	 	 	 	 
	 

	 	with a copy to:
	 	InterMune, Inc.
	 

	 	 	 	3280 Bayshore Boulevard
	 

	 	 	 	Brisbane, CA 94005 USA
	 

	 	 	 	Facsimile: +1 — 415 – 466-2300
	 

	 	 	 	Attention: General Counsel
	 
	 	 	 	 
	 

	 	If to BI Austria:
	 	Boehringer Ingelheim Austria GmbH
	 

	 	 	 	Dr. Boehringer-Gasse 5 – 11
	 

	 	 	 	A-1121 Vienna, Republic of Austria
	 

	 	 	 	Facsimile: +43 – 1 – 801 05 – 2440
	 

	 	 	 	Attention: Monika Henninger
	 

	 	 	 	Business Support Biotech
	 
	 	 	 	 
	 

	 	with a copy to:	 	 
	 

	 	 	 	Boehringer Ingelheim GmbH
	 

	 	 	 	Binger Strasse 173
	 

	 	 	 	D-55 216 Ingelheim am Rhein
	 

	 	 	 	Facsimile: +49 – 61 32 77 – 98 287
	 

	 	 	 	Attention: Rolf G. Werner
	 

	 	 	 	Corporate Division Biopharmaceuticals”

	 	10.	 	The parties understand and agree that InterMune intends [ * ] to [ * ] in [ *
] The parties [ * ] in good faith [ * ] for the performance by BI Austria of
appropriate [ * ] required in order to [ * ] in [ * ] As a result, the parties, as
of the date hereof, have [ * ] which sets forth [ * ] A copy [ * ] is attached
hereto as Exhibit A, which [ * ] may be revised as agreed upon [ * ] Provided that [
* ] is successful, both parties intend for [ * ] to become [ * ] Accordingly, the
parties agree that they will [ * ] to [ * ] for the [ * ] by BI Austria, consistent
with [ * ] and the pricing at which BI Austria [ * ] and other related terms and
conditions, all of which will be set forth in a separate amendment, addendum or
agreement upon [ * ]

[ * ] = certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the securities and exchange
commission pursuant to rule 24b-2 on the securities exchange act
of 1934, as amended.

 

 

	 	 	 	Except as set forth above, all terms and conditions of the Agreement will remain in full force and
effect. Any capitalized term used herein and not otherwise defined will have the same meaning as
set forth in the Agreement. In the event of any conflict between this Amendment and the Agreement,
the terms of this Amendment shall govern to the extent of such conflict.
	 
	 	 	 	Please acknowledge your agreement to the above by countersigning both enclosed copies of this
letter where indicated below, and returning one original to the attention of Lucinda Y. Quan,
Director, Legal Affairs at InterMune, Tel: (415) 466-2223, Fax: (415) 466-2323. We would be happy
to proceed based on receipt of a facsimile copy while awaiting the original.

	 	 	 	 	 
	 

	Sincerely,	 	 
	 
	 	 	 	 
	 

	/s/ Russell Kawahata	 	 
	 
	 	 	 	 
	 

	Russell Kawahata	 	 
	 

	Vice President, Technical Operations
	  Acknowledged and Agreed:
	 
	 	 	 	 
	 

	InterMune, Inc.
	  Boehringer Ingelheim Austria GmbH
	 
	 	 	 	 
	 

	By:	/s/ Roger Hawley	  By:  	/s/ Kurt Konopitzky
	 

	 	 
	 	 
	 

	 	Roger Hawley,
	 	Dr. Kurt Konopitzky
	 

	 	Executive Vice President
	 	Head Division Biopharmaceuticals
	 

	 	Of Commercial and Technical Operations
	 	Division
	 
	 	 	 	 
	 

	Date: July 26, 2005
	  Date: July 26, 2005
	 
	 	 	 	 
	 

	 	 	  Boehringer Ingelheim Austria GmbH
	 
	 	 	 	 
	 

	 	 	  By:  	/s/ Monika Henninger
	 

	 	 	 	 
	 

	 	 	 	Dr. Monika Henninger
	 

	 	 	 	Head, Customer Relations & Projects
	 
	 	 	 	 
	 

	 	 	  Date: July 26, 2005

[ * ] = certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the securities and exchange
commission pursuant to rule 24b-2 on the securities exchange act
of 1934, as amended.

 

 

EXHIBIT A

[ * ]

[ * ] = certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the securities and exchange
commission pursuant to rule 24b-2 on the securities exchange act
of 1934, as amended.

 

 

Biopharmaceuticals/Operations

[ * ]

[ * ]

[ * ] = certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the securities and exchange
commission pursuant to rule 24b-2 on the securities exchange act
of 1934, as amended.exv4w1

 

EXHIBIT 4.1

FORM OF COMMON STOCK CERTIFICATE

	 	 	 
	COMMON STOCK

	 	COMMON STOCK
	 
	 	 
	Incorporated Under

the Laws of the State

of Maryland

	 	Shares

	 
	 	 
	
               NUMBER

   UD ___

	 	SEE REVERSE FOR

CERTAIN DEFINITIONS

[company logo]

United Dominion Realty Trust, Inc.

CUSIP 910197 10 2

THIS CERTIFIES THAT

[SPECIMEN]

is the owner of

FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, PAR VALUE $0.01 EACH IN

United Dominion Realty Trust, Inc. The holder and every transferee or
assignee of this certificate or shares represented hereby, or of any interest therein,
accepts and agrees to be bound by the provisions of the Articles of Incorporation of
the Company. This certificate and the shares represented thereby are transferable on
the books of the Company by the registered holder hereof in person or by attorney upon
surrender of this certificate properly endorsed. This certificate is not valid unless
countersigned by the Transfer Agent and registered by the Registrar.

In Witness Whereof, the Company has caused this certificate to be signed by the
facsimile signatures of its duly authorized officers.

Dated:                                         

COUNTERSIGNED AND REGISTERED:

WELLS
FARGO BANK, N.A.

TRANSFER AGENT AND REGISTRAR

	 	 	 	 	 	 	 
	BY:

	 	 
	 	 
	 	 
	 

	 	 
	 	 
	 	 
	 

	 	     AUTHORIZED SIGNATURE
	 	SECRETARY
	 	PRESIDENT AND

CHIEF EXECUTIVE OFFICER

 

 

(REVERSE)

UNITED DOMINION REALTY TRUST, INC.

     The shares of Common Stock represented by this certificate are subject to restrictions on
transfer for the purpose of the Corporation’s maintenance of its status as a real estate investment
trust under the Internal Revenue Code of 1986, as amended (the “Code”). No person may (1)
Beneficially Own or Constructively Own shares of Equity Stock in excess of 9.9% of the value of the
outstanding Equity Stock of the Corporation; or (2) Beneficially Own Equity Stock that would result
in the Corporation’s being “closely held” under Section 856(h) of the Code. Any Person who attempts
to Beneficially Own or Constructively Own shares of Equity Stock in excess of the above limitations
must immediately notify the Corporation. All capitalized terms in this legend have the meanings
defined in the Charter, as the same may be further amended from time to time, a copy of which,
including the restrictions on transfer, will be sent without charge to each stockholder who so
requests. If the restrictions on transfer are violated, the shares of Equity Stock represented
hereby will be automatically exchanged for shares of Excess Stock which will be held in trust by
the Corporation.

     The Company will furnish to the registered holder of this certificate on request, in writing,
without charge, the designations, relative rights, preferences and limitations applicable to each
class of authorized shares and the variations in rights, preferences and limitations determined for
each series within a class (and the authority of the Board of Directors to determine variations for
future series).

     The following abbreviations, when used in the inscription on the face of this certificate,
shall be construed as though they were written out in full according to applicable laws or
regulations:

TEN COM—as tenants in common

TEN ENT—as tenants by the entireties

JT ENT —as joint tenants with rightof survivorship and not
                    as tenant in common

UNIF GIFT MIN ACT .................Custodian.........................

                                             (Cust)                              (Minor)

	 	 	 
	under Uniform Gifts to Minors
	Act
	 	 
	 

	 	 
	 

	 	(State)

UNIF TRAN MIN ACT .................Custodian.........................

                                             (Cust)                              (Minor)

	 	 	 
	under Uniform Transfers to Minors
	Act
	 	 
	 

	 	 
	 

	 	(State)

Additional abbreviations may also be used though not in the above list.

For value received,                                          hereby sell, assign and transfer unto

PLEASE INSERT SOCIAL SECURITY OR OTHER

IDENTIFYING NUMBER OF ASSIGNEE

 

      

                                                                                                                                                                                                                            

PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE OF ASSIGNEE

                                                                                                                                                                                                                            

                                                                                                                                                                                                        Shares

of Common Stock represented by the within Certificate, and do hereby irrevocably constitute and appoint

                                                                                                                                                                                                        Attorney

to transfer the said Shares on the books of the within-named Company with full power of
substitution in the premises.

Dated                                         

      

                                                                                                                        

NOTICE: The signature to this assignment must correspond with the name as

written upon the face of the Certificate, in every particular, without

alteration or enlargement, or any change whatever.

      

SIGNATURE(S) GUARANTEED:                                                                                 

THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE
GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN
ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED
SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C.
RULE 17Ad-15.

     This certificate also evidences and entitles the holder hereof to certain Rights as set forth
in the First Amended and Restated Rights Agreement between United Dominion Realty Trust, Inc. (the
“Company”) and the Rights Agent dated as of September
14, 1999 (the “Rights Agreement”), the terms of which are incorporated herein by reference and a
copy of which is on file at the principal offices of the Company. Under certain circumstances, as
set forth in the Rights Agreement, such Rights will be evidenced by separate certificates and will
no longer be evidenced by this certificate. The Company will mail to each holder of this
certificate a copy of the Rights Agreement, as in effect on the date of mailing, without charge
promptly after receipt of a written request therefore. Under certain circumstances set forth in
the Rights Agreement, Rights that are owned or that were previously owned by a Person who is, was
or becomes an Acquiring Person or any Affiliate or Associate of an Acquiring Person may become null
and void.

Wells
Fargo Bank, N.A. is successor to Mellon Investor Services LLC as the
Rights Agent under the Rights Agreement.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}]]